Evidence map›Paper›PMID 35510959›Full record

ArticleHaemophilia : the official journal of the World Federation of Hemophilia2022

Platelet function testing: Current practice among clinical centres in Northern Europe.

Timea Szanto, Eva Zetterberg, Sofia Ramström, Eva B Leinøe, Pål A Holme, Jovan P Antovic, Margareta Holmström, Pall T Onundarson, Marika Pikta, Ines Vaide and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Haemophilia : the official journal of the World Federation of Hemophilia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Platelet function testing: Current practice among clinical centres in Northern Europe.Haemophilia : the official journal of the World Federation of Hemophilia · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 6 countries.

Timea SzantoCoagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.ORCID https://orcid.org/0000-0001-7006-6564
Eva ZetterbergDepartment of Translational Medicine & Centre for Thrombosis and Haemostasis, Lund University, Malmö, Sweden.ORCID https://orcid.org/0000-0003-1775-1727
Sofia RamströmDepartment of Clinical Chemistry and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Eva B LeinøeDepartment of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Pål A HolmeDepartment of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Jovan P AntovicCoagulation Research, Institute for Molecular Medicine and Surgery, Karolinska Institute & Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
Margareta HolmströmDepartment of Health and Department of Acute Internal Medicine and Geriatrics, Medicine and Caring Sciences Linköping University, Linköping, Sweden.
Pall T OnundarsonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Marika PiktaLaboratory, North Estonia Medical Centre, Tallinn, Estonia.
Ines VaideDepartment of Hemato-Oncology, University of Tartu, Institute of Clinical Medicine, Tartu, Estonia.
Anna OlssonRegion Västra Götaland, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID https://orcid.org/0000-0002-9974-4880
Maria MagnussonDepartment of Haematology and Coagulation Disorders, Sahlgrenska University Hospital, Gothenburg, Sweden.
Satu KärkkäinenHemostasis and Platelet Laboratory, Fimlab Laboratoriot, Tampere, Finland.
Manar BitarDepartment of Laboratory Medicine, Clinical Chemistry, Faculty of Medicine and Health, Örebro University Hospital, Örebro, Sweden.
Lone Hvitfeldt PoulsenCentre for Haemophilia and Thrombosis, Aarhus University Hospital, Aarhus, Denmark.
Riitta LassilaCoagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.ORCID https://orcid.org/0000-0002-1911-3094
Nordic Haemophilia CouncilCoagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Linköping University · SESahlgrenska University Hospital · SEUniversity of Helsinki · FIAarhus University Hospital · DKCopenhagen University Hospital · DKFimlab (Finland) · FIKarolinska University Hospital · SELund University · SENorth Estonia Medical Centre · EEÖrebro University Hospital · SEOslo University Hospital · NOUniversity of Iceland · ISUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPlatelet function tests are used to screen and diagnose patients with possible inherited platelet function defects (IPFD). Some acquired platelet dysfunction may be caused by certain drugs or comorbidities, which need to be excluded before testing.

aimsTo identify current practice among centres performing platelet function tests in Northern Europe.

methodsA total of 14 clinical centres from Sweden (six), Finland (two), Denmark (two), Norway (one), Estonia (two) and Iceland (one) completed the survey questionnaire, the population capture area of about 29.5 million.

resultsSix of the 14 (42.8%) centres providing platelet function assessment represent comprehensive treatment centres (EUHANET status). A Bleeding score (BS) or ISTH bleeding assessment tool (ISTH BAT score) is evaluated in 11/14 (78.6%) centres and family history in all. Five/14 centres (35.7%) use structured preanalytical patient instructions, and 10/14 (71.4%) recorded questionnaire on the preassessment of avoidance of any drugs or natural products affecting platelet functions. Preliminary investigations of screening tests of coagulation are performed in 10/14 (71.4%), while in 4/14 (28.6%), the diagnostic work-up of IPFD and von Willebrand disease (VWD) is performed simultaneously. The work-up of IPFD includes peripheral blood smear in 10/14 (71.4%), platelet aggregometry in all, flow cytometry in 10/14 (71.4%) and Platelet Function Analysis (PFA) in 3/11 (28.6%). Molecular genetic diagnosis is available in 7/14 (50%) centres.

conclusionsThe considerable variability in the current practice illustrates the need for harmonization between the Northern European centres according to the international registers (i.e. EUHASS) and IPFD guidelines (ISTH, EHA).

Indexed as

Blood Platelet Disordersvon Willebrand DiseasesBlood PlateletsEuropeHemorrhageHumansPlatelet Function Testsblood platelet disordersdata collectionplatelet function testingplateletssurvey

Identifiers

PMID35510959
PMCPMC9540416
OpenAlexW4229044157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.